Evaluaciones económicas
Published on 15 de marzo de 2022 | http://doi.org/10.5867/medwave.2022.02.002118
Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru
Sensitivity analysis from Ministry of Health and Social Security Health Insurance
